[go: up one dir, main page]

MX2009013913A - Cristales nuevos de 4-{ 3- [ 4- ( 3- { 4- (amino(butoxicarbonilimi no) metil) fenoxi } propil -1- piperidinil ] propoxi } -n'-(butoxicarbonil) benzamidina. - Google Patents

Cristales nuevos de 4-{ 3- [ 4- ( 3- { 4- (amino(butoxicarbonilimi no) metil) fenoxi } propil -1- piperidinil ] propoxi } -n'-(butoxicarbonil) benzamidina.

Info

Publication number
MX2009013913A
MX2009013913A MX2009013913A MX2009013913A MX2009013913A MX 2009013913 A MX2009013913 A MX 2009013913A MX 2009013913 A MX2009013913 A MX 2009013913A MX 2009013913 A MX2009013913 A MX 2009013913A MX 2009013913 A MX2009013913 A MX 2009013913A
Authority
MX
Mexico
Prior art keywords
crystals
butoxycarbonylimino
benzamidine
butoxycarbonyl
piperidinyl
Prior art date
Application number
MX2009013913A
Other languages
English (en)
Inventor
Naokatu Aoki
Junichi Mitsuyama
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2009013913A publication Critical patent/MX2009013913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROBLEMAS. Proporcionar cristales nuevos de 4-{3-4[-(3-{4-[amino(b utoxicarbonilimino)metil]fenoxil}propil}-1-piperidinil]propoxi}-N '-(butoxicarbonil)benzamidina.FORMAS DE RESOLVER LOS PROBLEMAS. El cristal tipo II, el cristal tipo III y el cristal tipo IV de 4-{3-[4-(3-{4-[amino(butoxicarbonilimino)metil]fenixi}propil}-1-p iperidinil]propoxi}-N'-(butoxicarbonil)benzamidina son útiles como sustancias farmacéuticas excelentes de agentes antimicóticos.
MX2009013913A 2007-07-04 2008-07-02 Cristales nuevos de 4-{ 3- [ 4- ( 3- { 4- (amino(butoxicarbonilimi no) metil) fenoxi } propil -1- piperidinil ] propoxi } -n'-(butoxicarbonil) benzamidina. MX2009013913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007176106 2007-07-04
PCT/JP2008/061944 WO2009005077A1 (ja) 2007-07-04 2008-07-02 ４－｛３－［４－（３－｛４－［アミノ（ブトキシカルボニルイミノ）メチル］フェノキシ｝プロピル）－１－ピペリジニル］プロポキシ｝－ｎ’－（ブトキシカルボニル）ベンズアミジンの新規な結晶

Publications (1)

Publication Number Publication Date
MX2009013913A true MX2009013913A (es) 2010-03-10

Family

ID=40226120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013913A MX2009013913A (es) 2007-07-04 2008-07-02 Cristales nuevos de 4-{ 3- [ 4- ( 3- { 4- (amino(butoxicarbonilimi no) metil) fenoxi } propil -1- piperidinil ] propoxi } -n'-(butoxicarbonil) benzamidina.

Country Status (22)

Country Link
US (1) US8158800B2 (es)
EP (1) EP2189446B1 (es)
JP (1) JP5261386B2 (es)
KR (1) KR20100027176A (es)
CN (1) CN101730682B (es)
AU (1) AU2008272124B2 (es)
BR (1) BRPI0813104A2 (es)
CA (1) CA2691954C (es)
CY (1) CY1113210T1 (es)
DK (1) DK2189446T3 (es)
ES (1) ES2391319T3 (es)
HR (1) HRP20120796T1 (es)
IL (1) IL202804A (es)
MX (1) MX2009013913A (es)
NZ (1) NZ582187A (es)
PL (1) PL2189446T3 (es)
PT (1) PT2189446E (es)
RU (1) RU2456272C2 (es)
SI (1) SI2189446T1 (es)
TW (1) TWI395735B (es)
WO (1) WO2009005077A1 (es)
ZA (1) ZA201000027B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291617B2 (en) * 2002-03-06 2007-11-06 Toyama Chemical Co., Ltd. Arylamidine derivative or salt thereof
WO2006003881A1 (ja) * 2004-06-30 2006-01-12 Toyama Chemical Co., Ltd. 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤
ZA200805604B (en) * 2005-12-29 2009-12-30 Toyama Chemical Co Ltd Novel arylamidine derivative, salt thereof and antifungal agent containing those
PT2070536E (pt) 2006-10-06 2012-03-06 Toyama Chemical Co Ltd Composição farmacêutica que contém um derivado de fenilamidina e processo para utilização dessa composição farmacêutica em associação com um agente antifúngico

Also Published As

Publication number Publication date
PT2189446E (pt) 2012-10-25
NZ582187A (en) 2011-03-31
SI2189446T1 (sl) 2012-12-31
EP2189446A4 (en) 2010-10-20
IL202804A0 (en) 2010-06-30
CA2691954A1 (en) 2009-01-08
TW200914421A (en) 2009-04-01
EP2189446B1 (en) 2012-08-22
US8158800B2 (en) 2012-04-17
DK2189446T3 (da) 2012-09-24
CY1113210T1 (el) 2016-04-13
WO2009005077A1 (ja) 2009-01-08
EP2189446A1 (en) 2010-05-26
PL2189446T3 (pl) 2013-01-31
HRP20120796T1 (hr) 2012-10-31
JPWO2009005077A1 (ja) 2010-08-26
TWI395735B (zh) 2013-05-11
CA2691954C (en) 2014-10-28
ES2391319T3 (es) 2012-11-23
AU2008272124A1 (en) 2009-01-08
BRPI0813104A2 (pt) 2014-12-23
JP5261386B2 (ja) 2013-08-14
ZA201000027B (en) 2011-03-30
CN101730682A (zh) 2010-06-09
RU2456272C2 (ru) 2012-07-20
CN101730682B (zh) 2012-08-08
AU2008272124B2 (en) 2012-08-23
US20110046381A1 (en) 2011-02-24
RU2010103672A (ru) 2011-08-10
IL202804A (en) 2013-10-31
KR20100027176A (ko) 2010-03-10

Similar Documents

Publication Publication Date Title
SG155996A1 (en) Thermodynamically stable form of bay 43-9006 tosylate
MY145632A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20120861A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
UY38147A (es) Proceso de preparación
CU20080006A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
TW200716593A (en) Novel insecticides
CY1112590T1 (el) 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
NZ604035A (en) Glycine transporter-1 inhibitors, methods of making them, and uses thereof
ATE397601T1 (de) Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
TW200639157A (en) New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
MY148945A (en) Combination of a betamimetic with anticholinergics and/or steroids
TW200715966A (en) Synergistic fungicidal active compound combinations
MX2009013913A (es) Cristales nuevos de 4-{ 3- [ 4- ( 3- { 4- (amino(butoxicarbonilimi no) metil) fenoxi } propil -1- piperidinil ] propoxi } -n'-(butoxicarbonil) benzamidina.
UA92195C2 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений
SE0401968D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
NO20080053L (no) Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid
RU2008131044A (ru) Новое производное ариламидина, его соль и содержащий их противогрибковый агент
MY142268A (en) Processes for preparing biaryl boronic acids and n-protected n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide
UY27674A1 (es) Producto de inhalación en polvo que contiene el antagonista de cgrp, bibn4096, y procedimiento para su preparación.
UY28474A1 (es) Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhalado
TW200501956A (en) Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine
TW200516077A (en) Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder

Legal Events

Date Code Title Description
FG Grant or registration